RNAZ Short Volume
TransCode Therapeutics, Inc. (RNAZ) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $8.3M, listed on NASDAQ, employing roughly 12 people, carrying a beta of 1.24 to the broader market. TransCode Therapeutics, Inc. Led by Philippe Calais, public since 2021-07-08.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-07-16
- Short Volume
- 1.1K
- Total Volume
- 3.3K
- Short %
- 33.97%
- 30-Day Avg Short %
- 43.34%
Showing 30 days of FINRA short volume data for TransCode Therapeutics, Inc..
Learn how short volume is reported and how to read the data →
Frequently asked RNAZ short volume questions
- What is the daily RNAZ short volume?
- As of Jul 16, 2026, TransCode Therapeutics, Inc. (RNAZ) short volume is 1.1K shares against 3.3K total reported volume, or 33.97% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is RNAZ short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does RNAZ short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.